Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Multiple Sclerosis, MS. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation: A 1-Year Follow-up Study
Overview
The aim of this study is to investigate whether VISTA, a newly identified negative immune regulatory protein, differs in monocytes and T cells of patients diagnosed with Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS) compared to the same cell types in healthy controls. Additionally, the potential clinical correlation of VISTA expression in the follow-up of MS and CIS patients will be examined. By elucidating the role of VISTA in the pathophysiology of MS, this study will contribute to the literature by exploring its potential as a biomarker and its relevance in the development of novel therapeutic strategies. Specifically, this study will compare VISTA protein secretion in MS patients at the time of their first attack with that of healthy controls. Furthermore, changes in VISTA protein secretion will be assessed in blood samples collected at 6- and 12-month follow-ups, and the correlations of these changes with clinical and laboratory findings will be investigated. Finally, this study aims to determine whether CD4+ and CD8+ T cells, monocytes, and T regulatory (Treg) subgroups in the first attack blood samples of MS patients exhibit similar functional properties in terms of VISTA protein secretion as their counterparts in healthy controls. To achieve this, monocytes and T cell subtypes will be stimulated, and their pro- and anti-inflammatory cytokine responses will be analyzed.
Primary outcome measures
- VISTA Protein Secretion [Time frame: Baseline, Week 0]
Secondary outcome measures (2)
- Functional Comparison of Immune Cell Subsets via Cytokine Profiling and VISTA Expression Analysis [Time frame: Baseline, Week 0]
- Clinical and Radiological Correlation [Time frame: Baseline, Month 6, Month 12]
Eligibility criteria
Inclusion criteria
- Patients aged 18 years or older diagnosed with MS or CIS according to the 2017 McDonald criteria.
- No diagnosis of any autoimmune disease or malignancy.
- No new diagnosis of autoimmune disease or malignancy during the 1-year follow-up period.
- No use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling.
- No vaccination within one month prior to blood sampling.
- Not in the menstrual cycle at the time of blood sampling.
Exclusion criteria
- Age below 18 years.
- Presence of a previous or newly diagnosed autoimmune disease or malignancy at the time of blood sampling.
- Use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling.
- Vaccination within one month prior to blood sampling
- Being in the menstrual cycle at the time of blood sampling
- Patients without a definitive MS diagnosis according to the 2017 McDonald criteria will not be included in the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Turkey (Türkiye) · 2 centers
- Koc University — Istanbul
- Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric, Neurologic — Istanbul
Identifiers
NCT: NCT06957145 · Vista Protein Expression in MS